JP Morgan Chase
CSCI

JP Morgan Chase’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

JP Morgan Chase’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10
Closed -$15 – 7745
2024
Q2 		$15 Sell
10
-171
-94% -$1.3K ﹤0.01% 7186
2024
Q1 		$1.59K Sell
181
-30
-14% -$231 ﹤0.01% 6603
2023
Q4 		$1.23K Hold
211
– – ﹤0.01% 6807
2023
Q3 		$1.23K Sell
211
-17
-7% -$189 ﹤0.01% 6617
2023
Q2 		$1.33K Buy
228
+20
+10% +$228 ﹤0.01% 6417
2023
Q1 		$2K Buy
208
+20
+11% +$266 ﹤0.01% 6451
2022
Q4 		$2K Buy
+188
New +$2.79K ﹤0.01% 6350
2022
Q3 		– Sell
-228
Closed -$4K – 6920
2022
Q2 		$4K Sell
228
-145
-39% -$3.63K ﹤0.01% 6215
2022
Q1 		$14K Sell
373
-293
-44% -$10.5K ﹤0.01% 6146
2021
Q4 		$24K Sell
666
-80
-11% -$4.21K ﹤0.01% 6172
2021
Q3 		$56K Sell
746
-174
-19% -$12.4K ﹤0.01% 5804
2021
Q2 		$81K Sell
920
-54
-6% -$5.14K ﹤0.01% 5609
2021
Q1 		$111K Buy
974
+15
+2% +$1.66K ﹤0.01% 5348
2020
Q4 		$41K Buy
959
+19
+2% +$703 ﹤0.01% 5203
2020
Q3 		$34K Buy
940
+22
+2% +$975 ﹤0.01% 5051
2020
Q2 		$74K Buy
918
+7
+0.8% +$641 ﹤0.01% 4681
2020
Q1 		$47K Sell
911
-11
-1% -$1K ﹤0.01% 4748
2019
Q4 		$84K Hold
922
– – ﹤0.01% 4961
2019
Q3 		$95K Buy
922
+72
+8% +$15.6K ﹤0.01% 4922
2019
Q2 		$240K Sell
850
-18
-2% -$6.34K ﹤0.01% 4591
2019
Q1 		$403K Buy
868
+1
+0.1% +$388 ﹤0.01% 4308
2018
Q4 		$255K Buy
867
+58
+7% +$13.9K ﹤0.01% 4476
2018
Q3 		$118K Buy
809
+10
+1% +$1.83K ﹤0.01% 4887
2018
Q2 		$156K Sell
799
-10
-1% -$1.84K ﹤0.01% 4674
2018
Q1 		$118K Buy
809
+52
+7% +$10.2K ﹤0.01% 4542
2017
Q4 		$179K Buy
757
+189
+33% +$39.3K ﹤0.01% 4460
2017
Q3 		$120K Buy
568
+465
+451% +$85.6K ﹤0.01% 4251
2017
Q2 		$10K Buy
+103
New +$16.3K ﹤0.01% 4664
2014
Q4 		– Sell
-3
Closed -$43K – 4398
2014
Q3 		$43K Buy
+3
New +$38.4K ﹤0.01% 4120

Other funds holding CSCI

National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
PCMC
Planning Capital Management Corporation Paoli, Pennsylvania $151M AUM 30.62% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

JP Morgan Chase's CSCI Position: Q3 2024 in Review

JP Morgan Chase sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2024, closing a stake of 10 shares — an estimated $15 sold.

JP Morgan Chase first reported a position in CSCI in Q3 2014 and held it in 29 quarters. The position peaked at $403K in Q1 2019. 9 funds tracked by Wall St. Rank hold CSCI as of Q3 2024.

  • JP Morgan Chase reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • JP Morgan Chase sold 10 COSCIENS Biopharma Inc. Common Stock shares in Q3 2024, an estimated $15.
  • JP Morgan Chase first reported a position in COSCIENS Biopharma Inc. Common Stock in Q3 2014 and held it in 29 quarters.
  • JP Morgan Chase's COSCIENS Biopharma Inc. Common Stock position peaked at $403K in Q1 2019.
  • 9 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2024.

Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.